(S)-Thalidomide is the S-enantiomer of Thalidomide. (S)-Thalidomide causes teratogenic effects by binding to cereblon. (S)-Thalidomide has immunomodulatory, anti-inflammatory, antiangiogenic, and proapoptotic effects.

(S)-Thalidomide treatment results in a reduction in cell viability in U266 cells (IC50: 362 μM). (S)-Thalidomide treatment enhanced apoptosis in a dose-dependent manner in U266 cells. (S)-Thalidomide increases the Bax: Bcl-2 ratio, also increases I-kB protein levels and decreases NF-kB activity. A dramatic decrease in Bcl-2 expression with (S)-Thalidomide shows a possible enhancement of cytotoxic effect if combined with other cytotoxic agents [1].

(S)-Thalidomide is more teratogenic than (R)-Thalidomide. Thalidomide does cause limb reduction defects in chick embryos as long as the embryos are directly exposed to the drug. Thalidomide affects the chick limb grafted to a host embryo in a dose-response fashion [1].

841-67-8

C13H10N2O4

258.23

(S)-(-)-Thalidomide;(S)-Thalidomide

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years